Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 11:40:00 2024-09-13 EDT			5-day change	1st Jan Change
168.32 ^EUR	-0.13%		-0.44%	+16.62%

09-09	German Shares Cheer Likelihood of September ECB Rate Cut	MT
09-03	Merck Gets EU Approval for Keytruda Cancer Therapy	DJ

MERCK KGAA : UBS reiterates its Buy rating

August 01, 2024 at 07:45 am

Already positive, the research from UBS and its analyst Matthew Weston still consider the stock as a Buy opportunity. The target price is unchanged and still at EUR 178.

Latest news about Merck KGaA

German Shares Cheer Likelihood of September ECB Rate Cut	09-09	MT
Merck Gets EU Approval for Keytruda Cancer Therapy	09-03	DJ
Merck KGaA Doses First Patient in Late-stage Myasthenia Gravis Study	08-29	MT
Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis	08-29	CI
Chemical and pharmaceutical industry: research spending to remain virtually stable	08-29	DP
Merck KGaA Plans EUR800 Million Issuance of Subordinated Hybrid Instruments	08-20	MT
JPMorgan rates Merck KGaA at 'Overweight' - Target 190 euros	08-09	DP
MERCK KGAA : JP Morgan maintains a Buy rating	08-09	ZD
Bernstein: Sanofi Set to Record Growth on Expected Multiple Sclerosis Boost	08-08	MT
Biotech firm Recursion to buy smaller peer Exscientia for $688 million	08-08	RE
MERCK KGAA : UBS raises price target	08-07	CF
MERCK KGAA : Receives a Buy rating from UBS	08-06	ZD
MERCK KGAA : Gets a Buy rating from Deutsche Bank	08-06	ZD
MERCK KGAA : DZ Bank reaffirms its Buy rating	08-05	ZD
MERCK : All lights are green for a robust H2	08-02
Global markets live: Shell, Chevron, Boeing, Walt Disney, Qualcomm...	08-01
Germany's Merck KGaA Wraps Up Acquisition of US-based Mirus Bio	08-01	MT
Merck KGaA increases sales - Semiconductors and Pharmaceuticals provide support	08-01	DP
Transcript : Merck KGaA, Q2 2024 Earnings Call, Aug 01, 2024	08-01
MERCK KGAA : Jefferies gives a Buy rating	08-01	ZD
MERCK KGAA : UBS reiterates its Buy rating	08-01	ZD
MERCK KGAA : Gets a Buy rating from Barclays	08-01	ZD
MERCK KGAA : Deutsche Bank remains its Buy rating	08-01	ZD
MERCK KGAA : JP Morgan reiterates its Buy rating	08-01	ZD
Merck reports earlier-than-expected improvement in semiconductor market	08-01	RE

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Employees

62,176

Sector

Pharmaceuticals

Calendar

2024-10-16 - Capital Markets Day

More about the company